Neurodegeneration

BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...

NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...

MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...

BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...

TORONTO, Canada, July 15, 2026 Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC)...

NEWTON, Mass., July 7, 2026 Acumen Pharmaceuticals announced that it will present three scientific studies at the Alzheimer’s Association...

LONDON, UK, July 6, 2026 Cumulus Neuroscience announced a strategic collaboration with Muse by Interaxon to integrate validated at-home...

BOSTON, July 6, 2026 CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented...

STOCKHOLM, Sweden, June 22, 2026 BioArctic AB and Eli Lilly and Company have entered into a major research and...

BOSTON, MA and SEOUL, South Korea, June 22 2026 Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial...